March 16, 2022 02:10 PM EDT

Covid-19 vaccine marketing roundup: New data bolster case for J&J's single-dose vaccine ⁠— report; Germany inks deals with vaccine makers in preparation for future outbreaks

Nicole DeFeudis

Editor

Plagued by concerns around rare blood clots and reports of weaker immune responses, it appeared the fate of Johnson & Johnson’s Covid-19 vaccine was sealed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 vaccine marketing roundup: New data bolster case for J&J's single-dose vaccine ⁠— report; Germany inks deals with vaccine makers in preparation for future outbreaks

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Covid-19 vac­cine mar­ket­ing roundup: New da­ta bol­ster case for J&J's sin­gle-dose vac­cine ⁠— re­port; Ger­many inks deals with vac­cine mak­ers in prepa­ra­tion for fu­ture out­breaks

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Covid-19 vaccine marketing roundup: New data bolster case for J&J's single-dose vaccine ⁠— report; Germany inks deals with vaccine makers in preparation for future outbreaks

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life